Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects by Puja Sapra et al.
ORIGINAL PAPER
Potent and sustained inhibition of HIF-1a and downstream genes
by a polyethyleneglycol-SN38 conjugate, EZN-2208, results
in anti-angiogenic effects
Puja Sapra • Patricia Kraft • Fabio Pastorino • Domenico Ribatti •
Melissa Dumble • Mary Mehlig • Maoliang Wang • Mirco Ponzoni •
Lee M. Greenberger • Ivan D. Horak
Received: 18 November 2010 / Accepted: 13 March 2011 / Published online: 31 March 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Topoisomerase I inhibitors down-regulate HIF-
1a leading to tumor growth inhibition, but only while
maintaining sustained levels of drug exposure. EZN-2208, a
multi-arm 40 kDa pegylated, releasable SN38-drug conju-
gate, provides higher, longer lasting exposure of tumors to
SN38 in contrast to SN38 that is released from CPT-11.
EZN-2208 also consistently has greater antitumor activity
than CPT-11 in a variety of solid and hematological tumor
models. In this report, the ability of PEG-SN38 to down-
regulate HIF-1a and its downstream targets, in a more potent,
sustained manner compared with CPT-11 was examined. To
do so, U251 glioma xenografts that stably expressed a
hypoxia response element-dependent luciferase reporter
gene were implanted in mice. After treatment it was found
that EZN-2208 induced potent, sustained HIF-1a down-
regulation (37% at 48 h and 83% at 120 h) in the tumors,
whereas CPT-11 caused only minor, transient HIF-1a down-
regulation. In addition, EZN-2208 down-regulated mRNA
levels of HIF-1a targeted genes (MMP2, VEGF1, Glut1,
Glut3 and TGFb1). Further, western blot analyses of xeno-
graft tumors demonstrated that EZN-2208 had significantly
more effect than CPT-11 in down-regulating HIF-1a, VEGF,
Glut1 and MMP2 protein levels. Significant down-regula-
tion of HIF-1a and VEGF proteins translated to EZN-2208’s
superior anti-angiogenic activity compared with CPT-11,
confirmed by microvessel density reduction in a chorioa-
llantoic membrane assay and in CD-31 immunohistochem-
istry studies. Additional studies done with matrigel implants
devoid of tumor cells show that EZN-2208 significantly
inhibits angiogenesis while CPT-11 has little or no effect. It
is concluded that the superior antitumor activity of EZN-
2208 compared with CPT-11 is attributed, in part, to an anti-
angiogenic effect. Ongoing clinical Phase I and Phase II
studies will assess safety and efficacy of EZN-2208.
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Hypoxia-inducible factor 1 (HIF-1), a master regulator of
transcriptional responses of mammalian cells to oxygen
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deprivation, plays a critical role in the expression of many
genes that control angiogenesis, glucose metabolism, cell
proliferation, cell survival, and metastasis in response to
hypoxia [1, 2]. Elevated expression of the alpha subunit of
HIF-1 (HIF-1a) is associated with poor prognosis in many
types of solid tumors such as lung, breast, colorectal, brain,
pancreatic, ovarian, renal, and bladder cancers [3]. In
addition, HIF-1 is involved in the up-regulation of down-
stream VEGF that exerts pro-angiogenic effects on the
tumors’ vascular endothelial cells, resulting in increased
vascular permeability and neo-angiogenesis [4–7]. Since
elevated HIF-1a expression correlates with neo-angiogen-
esis, drug resistance and overall poor treatment outcome,
compounds that inhibit HIF-1a may have broad utility in
the control of cancer [2, 8].
In recent years, strategies to identify direct and indirect
inhibitors of HIF-1a that function by blocking HIF-1a
expression levels and/or activity have been developed,
including cell-based reporter screens, antisense approaches,
targeting key protein–protein interactions, increasing HIF-
1a protein turnover or utilizing HIF oligonucleotide decoy
[9]. Topoisomerase I inhibitors, including camptothecin
analogs and topotecan, were identified as HIF-1a inhibitors
in a high throughput cell-based HRE-luciferase reporter
screen [10]. Melillo et al. demonstrated that topotecan
inhibits HIF-1a, leading to a marked decrease in angiogen-
esis and to significant tumor growth inhibition [11, 12].
However, these effects were achieved only when the top-
isomerase I inhibitor (for example, topotecan) was admin-
istered on a daily schedule, and not when the drug was given
on an intermittent schedule [11]. Based on these preclinical
data, clinical strategies should aim at identifying the opti-
mum dose and schedule of topoisomerase I inhibitors that
would achieve continuous suppression of HIF-1.
Camptothecin-11 (CPT-11; Camptosar, irinotecan), is a
topoisomerase I inhibitor that upon hydrolysis by carboxy-
lesterase 2 yields the active moiety, SN38 (10-hydroxy-7-
ethyl-camptothecin). EZN-2208 is a pegylated-SN38 drug
conjugate made by linking SN38 to a 40 kDa 4-arm poly-
ethylene glycol (PEG) molecule [13] (Fig. 1, supplement).
Upon addition to plasma, SN38 is released, thereby mediating
the cytotoxic action of the compound. We have previously
shown in preclinical xenograft models (including an in vivo
CPT-11 resistance model), that EZN-2208 has a significantly
enhanced efficacy compared with CPT-11 when both the
drugs were compared at their respective maximum tolerated
doses [14–16]. We have also shown that when compared at
their respective MTDs, EZN-2208 provides higher and longer
lasting exposure of tumors to SN38 via preferential accu-
mulation of EZN-2208 in the solid tumors (enhanced per-
meability and retention effect) compared with CPT-11 [15],
which could explain improved efficacy of EZN-2208 over
CPT-11. Thus, we hypothesized that, due to favorable
pharmacokinetic and biodistribution properties of EZN-2208,
this molecule will work as a sustained delivery system for
SN38 and, therefore, will down-regulate HIF-1a in a more
potent and sustained manner compared to CPT-11. In this
report, we evaluate this hypothesis using the U251-HRE
xenograft model system [10]. We demonstrate that sustained
SN38 delivery by EZN-2208 down-modulates HIF-1a pro-
tein, down regulates the expression of proteins controlled by
HIF-1a, in particular VEGF, and has more anti-angiogenic
activity compared to CPT-11.
Materials and Methods
Xenografts and Bioluminescence imaging
U251-HRE xenografts (cells kindly provided by Dr. Melillo,
NIH, Rockville, MD) were established in the flanks of female
nude mice by injecting 1 9 107 cells. When tumors reached
100 mm3, the mice received EZN-2208 or CPT-11 at their
respective MTDs (single or multiple dosing regimen). Lucif-
erase expression in the U251-HRE tumors was measured using
bioluminescence (BL) (Xenogen IVIS 100 Imaging Station,
Xenogen Corp.) following firefly D-luciferin (150 mg/kg, IP)
injection at 0, 48 and 120 h from start of treatment. Because
treatment reduced tumor mass (data not shown), BL values
(total flux/photon/second, determined using the Xenogen
Live Image Analysis software) were normalized for tumor
mass. The percent of tumor BL/mg tumor mass remaining at
each time point, relative to the zero-time baseline for each
respective treatment group, was calculated. It is important to
note that the doses of EZN-2208 stated in this article refer to
SN38 equivalents. For example, a dose of 30 mg/kg EZN-
2208 means that the dose contains 30 mg/kg of SN38 and
870 mg/kg (29-fold higher) of the whole conjugate, assuming
that the loading of SN38 in the whole EZN-2208 is 3.45%.
Relative quantification RT-PCR mRNA analysis
and Western Blot protein analysis
Tumors were collected from U251-HRE xenografts at 48 and
120 h after receiving a single intravenous MTD treatment of
either EZN-2208 or CPT-11. Total cellular RNA was
extracted using Ambion RNAqueous kit and converted to
cDNA using a high capacity cDNA reverse transcription kit
(Applied Biosystems). HIF-1a, Glut1, Glut3, VEGF1,
TGFBR1 and MMP2 mRNA were measured individually by
TaqMan gene expression and normalized by co-amplifica-
tion of the reference gene, 18S rRNA. Results were quanti-
tated with RQ Manager Software analysis. Differences
between effects were determined by unpaired, two-tailed
t test with Welch correction. For protein analysis, tumors
(120 h samples, 1–5 mg) were lysed in SDS–PAGE sample
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buffer. Each sample (10 lg total proteins) was added to
4–20% SDS–PAGE gels, migration monitored at 150 volts
for 1 h, and the protein bands transferred to nitrocellulose
membrane. The membrane was incubated with antibodies
(anti-HIF-1a, anti-a-tubulin antibody, anti-MMP2 antibody,
anti-VEGF antibody, or anti-Glut1 antibody) at 4C for 16 h
and labeled proteins detected with 0.1 lg/mL HRP-labeled
anti-mouse IgG antibody (HIF-1a/ab-51608 or a-tubulin/ab-
56676) or anti-rabbit IgG antibody (MMP2/ab52756, VEGF/
ab-52917 or Glut1/ab18106) at 23C for 1 h. After ECL
detection reagent development, the membranes were imaged
with the FUJIFILM LAS 3000.
Chorioallantoic membrane assay
Chorioallantoic membrane experiments were performed as
previously described [17]. Naı¨ve U251-tumor biopsy
fragments (1–2 mm3) were grafted onto the CAM, incu-
bated with PBS-control or with a single bolus of either
EZN-2208 or CPT-11. On day 12, the angiogenic response,
as determined by the number of vessels converging toward
the grafts, was evaluated. CAMs were then processed for
light- and dark-field microscopy, as previously described
[18]. Microvessels density was expressed as the percentage
of the total number of intersection points occupied by
CD31-positive vessels cut transversely (diameter, 3–10
lm) and mean values ± SEM determined.
Matrigel plug assay
The matrigel angiogenesis assay was modified based on
previously described methods [19, 20]. In brief, matrigel
(BD Biosciences) was prepared with or without 1 lg/ml
basic-FGF (bFGF). Six week old female nude mice, which
were anesthetized with Isoflurane, were then injected with
matrigel subcutaneously in the ventral midline. No longer
than 30 min following the implantation of matrigel, mice
were administered intravenously a single dose of saline,
EZN-2208 at 30 mg/kg, or CPT11 at 80 mg/kg. Six days
later, the matrigel plugs were excised, photographed and














































































Fig. 1 HIF-1a dependent luciferase expression inhibition in a U251-
HRE glioblastoma xenograft following treatment with EZN-2208 or
CPT-11 using a single or b multiple dosing regimes. A Single, IV, qdx1
treatment of EZN-2208 (30 mg/kg) or CPT-11 (80 mg/kg). B Multiple,
IV, q2dx3 treatment of EZN-2208 (10 mg/kg) or CPT-11 (40 mg/kg).
Left panels The percent of tumor bioluminescence remaining 48 h (gray)
and 120 h (black) post-treatment compared to baseline (white). Right
panels Images acquired at baseline and 120 h post-treatment. Graph
depict mean ± SEM luminescence normalized to group average
(*P \ 0.05; **P \ 0.01)
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weighed. Plugs were homogenized and analyzed for
hemoglobin content using the Drabkin’s assay according to
manufacturer’s instructions (Sigma D5941). A Mann–
Whitney test was used to determine statistical significance.
Histological analysis
U251-HRE xenografts were administered, intravenously, a
single dose of saline at the MTD of EZN-2208 (30 mg/kg) or
CPT-11 (80 mg/kg). Five days after last treatment, the mice
were sacrificed, tumors were collected, paraffin-embedded
and stored until sectioned. Sections were de-paraffinized, re-
hydrated and processed for antigen retrieval as described
before [21]. The sections were stained with a primary anti-
body against CD31 (clone SC-1506 Santa Cruz Biotech-
nology). Morphometric analysis for CD31-labeled areas was
performed on nine randomly selected fields, within three
separate sections, with an Image Analysis software-equip-
ped Olympus photomicroscope (Olympus Italia) (9200
magnifications). The mean CD31-positive microvessels
value ± SEM of the nine fields per section and the final
mean value for all three sections within a treatment group
were calculated. Differences between means were deter-
mined by Student’s t test at P B 0.05 (GraphPad Prism 3.0).
Results and discussion
EZN-2208 preferentially inhibits HIF-1-dependent
luciferase expression compared with CPT-11
The U251-HRE cell line expresses a luciferase reporter
controlled by a hypoxia response element that has shown
up to 12-fold induction of in vitro luciferase expression
under hypoxic (1% O2) conditions [10, 22] and been used
to investigate the HIF-1a associated antitumor activity of
topotecan by BL imaging [11]. We compared the efficacy
of EZN-2208 and CPT-11, as single or multiple doses at
their respective MTDs, to inhibit HIF-1-dependent lucif-
erase expression and tumor growth in U251-HRE xeno-
grafts. It is important to note that since the PEG-component
of EZN-2208 has no toxicity or antitumor activity, the
activity of EZN-2208 is derived from SN38 that is released
from the conjugate. In contrast, the cytotoxic activity of
CPT-11 can be due to CPT-11 itself (the prodrug) as well
as SN38 derived from CPT-11 [23]. Based on pharmaco-
kinetic studies in mice, it is estimated that 1.5% SN-38 is
derived from CPT-11 [14]. Since SN38 is approximately
100- to 1,000-fold more potent than CPT-11 [14], the
activity of CPT-11 is derived from both drugs. The MTD of
each of these compounds were chosen since our intent was
to study the mechanistic basis of the maximal antitumor
effect. At the MTDs, in either CPT-11 or EZN-2208 groups
using a single or multidose schedule, no animal deaths
were observed and body weight loss is routinely less than
5% pretreatment animal weight.
While the saline-treated mice had progressive increases
in luminescence (data not shown), both the single and
multiple EZN-2208-treatment groups had diminished
luminescence at 48 and 120 h time points post Day 1 of
treatment. CPT-11 treatment had minimal effect on lumi-
nescence by 48 h, even following multiple doses (Fig. 1a,
b-right panels). Because the tumor mass was reduced by
both EZN-2208 and CPT-11 treatment (data not shown),
the luminescence (total flux/photons/s) was normalized for
tumor mass and expressed in terms of percent change from
each respective group’s baseline BL reading. A single dose
of EZN-2208 induces potent and sustained down-regula-
tion via the HIF-1a-luciferase regulated hypoxia response
element (37% at 48 h and 83% at 120 h) compared to no
down-regulation by a single injection of CPT-11 (Fig. 1a-
left panel). When given on multiple days (Day 0, 2, 4),
EZN-2208 induces a very potent down-regulation of HIF-
1a (38% by 48 h and 93% by 120 h) (Fig. 1b-left panel)
while CPT-11 causes only a modest 15% (48 h) and 32%
(120 h) down-regulation. This observation agrees with
Rapisarda et al., in which daily, but not intermittent,
administration of topotecan, another topoisomerase I
inhibitor, resulted in a sustained tumor growth inhibition
[7]. Beyond this, since weight loss after administration of
EZN-2208 or CPT-11 is mild (maximally 5 and 3% pre-
treatment weight, respectively) and transitory (recovery by
day 5 or 6), while the down regulation of HIF-1a occurs on
day 2 and intensifies on day 5, it is unlikely that the anti-
angiogenic effects are due an indirect effect of the com-
pounds on weight loss. Thus, a continued delivery system
of SN38 by EZN-2208 can down-regulate HIF-1a in a
more potent and sustained manner compared to CPT-11.
EZN-2208 down-regulates mRNA levels of HIF-1a
targeted genes
HIF-1 inhibitor therapy can target the HIF-1 pathway at
several levels, including decreasing HIF-1 mRNA or pro-
tein levels or decreasing HIF-1-mediated trans-activation
of downstream targets. To further confirm the role EZN-
2208 plays in the inhibition of the U251-HRE’s HIF-1a
dependent luciferase expression and to determine the level
of the inhibition, the intra-tumor HIF-1a and downstream
HIF-1-target (VEGF, Glut 1, Glut2, and TGFb1) mRNAs
were determined by RT-PCR, 48 and 120 h after a single
injection (iv.) of either EZN-2208 (30 mg/kg) or CPT-11
(80 mg/kg) (Fig. 2a–f). These downstream targets play
different roles in malignant cell survival. VEGF (VEGFR-
1) and MMP2 genes are involved in pro-angiogenesis and
vascular stability, increasing under the hypoxic conditions.
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Glut1 and Glut3 play critical roles in cellular metabolism
and glucose transport where enhanced glucose metabolism
is observed following up-regulation of their respective
genes by hypoxia. TGFb1 stimulates cell proliferation [2,
24]. The stabilization of HIF-1a proteins in the tumor’s
hypoxic environment, its translocation to the nucleus where
it complexes with HIF-1b, has been linked with the acti-
vation of these target genes that are important for cell
survival under hypoxic conditions [24].
HIF-1a mRNA levels (Fig. 2a) were not significantly
changed (relative to vehicle-treated group) at 48 h and
down-regulated slightly (20%) at 120 h in U251-HRE
xenograft tumors following a single injection of EZN-2208
(30 mg/kg) while no down-regulation by CPT-11 was
observed. The results are consistent with those reported by
Rapsirada et al., where topotecan did not affect HIF-1a
mRNA accumulation or protein half-life, but did inhibit its
translation [12]. However, the single dose of EZN-2208, by
120 h post-treatment, significantly down-regulated the
mRNA of the downstream HIF-1a targeted genes, includ-
ing MMP2 (67%), VEGF1 (92%), Glut1 (75%), Glut3
(77%), and TGFb1 (54%) (Fig. 2b–f). Only VEGF1
mRNA levels were decreased by CPT-11 at both 48 (62%)
and 120 h (59%) (Fig. 2d). Glut1 and Glut3, were slightly
down-regulated by CPT-11 at both 48 and 120 h (Glut1—
16% and 30%, Glut3—54% and 38%, respectively). The
mRNA levels of all the other down-stream HIF-1a targeted
genes were unchanged following CPT-11 treatment, at both
time points (Fig. 2e–f).
EZN-2208 down-regulates protein levels of HIF-1a,
VEFG, Glut1 and MMP2
Increased HIF-1a protein in cancer cells translocates to
the nucleus, complexes with HIF-1b and activates multi-
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Fig. 2 RT-PCR analysis for mRNA expression in U251-HRE-
xenograft tumors at 48 and 120 h after a single IV injection of
EZN-2208 (30 mg/kg) or CPT-11 (80 mg/kg). mRNA RQ% for
VEGF1, MMP2, GLUT1, GLUT3 and TGFb1 from Saline control
(white), EZN-2208 (gray) and CPT-11 (dark gray)
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metabolic adaptation (Glut1), vascular stability and
metastasis (MMP2) and, ultimately survival; thereby
driving tumor progression [2, 24]. Western blot analyses
(Fig. 3) of U251-HRE tumors from EZN-2208-treated
mice indicated that EZN-2208 reduces the accumulation
of HIF-1a protein, significantly reducing the protein levels
of VEGF, Glut1 and MMP2. Microtubule abundance
(minimal a-tubulin decrease detected) is not altered as a
result of treatment. The tumors from mice similarly
treated with CPT-11 showed a slight reduction in HIF-1a
protein levels and less effect on downstream VEGF and
Glut1 protein levels as compared to EZN-2208. There
was little effect on MMP2 or a-tubulin levels with CPT-
11 treatment.
Fig. 3 Western blot analyses for HIF-1a, VEGF, Glut1, MMP2 and
a-tubulin expression in U251-HRE-xenograft tumors at 120 h after a
single IV injection of EZN-2208 (30 mg/kg) or CPT-11 (80 mg/kg).
Protein expression levels in tumors isolated from individual mice,

























Fig. 4 Impact of EZN-2208 on
angiogenesis by chorioallantoic
membrane (CAM) assay CAMs
grafted from naive U251-HRE
glioma tumor fragments were
photographed in ovo with a
camera-equipped
stereomicroscope (509)
following PBS, CPT-11 or
EZN-2208 treatment as
described. Images were taken
using light and dark field
microscopy as depicted in the
upper and lower set of figures.
Graph depicts the mean
percent ± SEM of CD31-
positive vessel density
(**P B 0.01; ***P B 0.001)
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Effect of EZN-2208 on angiogenic responses
in the CAM assay, in tumors grown on the flank of nude
mice, and the matrigel plug assay
To determine if the decreased VEGF protein levels
observed after EZN-2208 treatment might improve anti-
angiogenic effects over that observed with CPT-11, the
anti-angiogenic activity of EZN-2208 and CPT-11 was
studied using the in vivo CAM assay. In this assay, anti-
angiogenic substances can cause differences in the extent
and pattern of vessel branching following the implantation
of the tumors, which are harvested from mice, and grown
on the CAM in the presence of test agents. CAMs incu-
bated with either CPT-11 or EZN-2208 showed a signifi-
cant decrease in allantoic vessels radiating in a ‘‘spoked
wheel’’ pattern towards the xenografts compared to PBS-
treatment control CAMs (Fig. 4a, light and dark-field
micrographs). Morphometric assessment of microvessel
density also indicated that both compounds were effec-
tive, although EZN-2208 had a more pronounced effect
(CPT-11 vs. control, P \ 0.01; EZN-2208 vs. control,
P \ 0.001) (Fig. 4b).
The anti-angiogenic properties of CPT-11 vs. EZN-
2208, as assessed by the amount of blood vessels in tumors
treated with these agents was also compared. To do so,
tumor expression of the blood vessel endothelial marker,
CD31 was assessed using IHC methodology. It was found
that both treatments exerted anti-angiogenic activities
which resulted in decreased CD31 staining compared to
PBS-treated tumors (Fig. 5) and however, the EZN-2208
Fig. 5 IHC evaluation of CD31 expression levels in subcutaneous
U251-HRE-derived xenograft tumors at low (a) and high magnifica-
tion (b). Nude mice engrafted with U251-HRE cells, were injected
with a single bolus of CPT-11 (80 mg/kg) or EZN-2208 (30 mg/kg).
Tumors were harvested 5 days after the treatment and tissue sections
were immunostained for CD31 to show tumor angiogenesis. Scale bar
200 (a) and 100 (b) lm. c Gaphs depict mean ± SEM CD31 staining
(*P \ 0.05; **P \ 0.01)
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treatment resulted in a significant increase in anti-angio-
genic effect compared to CPT-11 (P \ 0.05). Similar
results have also been observed with tumors derived from
neuroblastoma cell lines [16].
To further compare the anti-angiogenic properties of
CPT-11 vs. EZN-2208, the ability of these compounds to
inhibit the infiltration of blood vessels into a matrigel plug
embedded with bFGF was examined. Hemaglobin content
was used to estimate amount of blood vessel that grew into
the matrigel plug and has been previously validated as an
acceptable assay [19]. Since no tumor cells were present in
the matrigel plug, the effects of candidate anti-angiogenic
effects are likely to be on endothelial cells. As shown in
Fig. 6a, addition of bFGF stimulated hemoglobin content
in the plug by approximately fivefold and is consistent with
previous reports [20]. EZN-2208 significantly reduced
hemoglobin content in the bFGF-embedded matrigel plug
almost to the same values in matigel plugs devoid of bFGF.
In contrast, CPT-11 had no significant effect. The conclu-
sions were consistent with visual observation of the ma-
trigel plugs (Fig. 6b).
Conclusions
In conclusion, data presented here and previously pub-
lished by Mellilo et al. [6–8], strongly argues for sustained
inhibition of HIF-1a to achieve therapeutically meaningful
responses in preclinical models. Clinical trials sponsored
by the NCI are ongoing to explore the hypothesis that
chronic administration of topotecan inhibits HIF-1a
expression and angiogenesis in patients with metastatic
tumors over-expressing HIF-1a (www.clinicaltrials.gov).
Our data argues that high and sustained SN38 delivery by
EZN-2208 down-modulate HIF-1a protein and further
downstream regulated genes and proteins, in particular
VEGF, in a long lasting manner. This mechanism, along
with direct effects on the tumor vasculature, may contrib-
ute to improved efficacy of EZN-2208 over CPT-11 that
has been observed in several preclinical xenograft models,
including CPT-11 refractory tumor models [14].
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Fig. 6 Nude mice were
implanted with matrigel
containing bFGF or devoid of
bFGF. Immediately after the
implant, animals were given a
single dose of saline, 30 mg/kg
EZN-2208 or 80 mg/kg CPT-
11. Animals that received EZN-
2208 and CPT-11 had implants
of matirgel plugs with bFGF.
After 6 days, matigel plugs
were excised, photographed,
and hemoglobin content/gm of
plug weight was measured.
a Graph depicts mean
value ± SEM (*P = 0.0314; ns
not significant). b Visual
observation of excised matrigel
implants
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